HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Caramiphen edisylate as adjunct to standard therapy attenuates soman-induced seizures and cognitive deficits in rats.

Abstract
The progression of epileptiform activity following soman (GD) exposure is characterized by a period of excessive cholinergic activity followed by excessive glutamatergic activity resulting in status epilepticus, which may lead to neuropathological damage and behavioral deficits. Caramiphen edisylate is an anticholinergic drug with antiglutamatergic properties, which conceptually may be a beneficial therapeutic approach to the treatment of nerve agent exposure. In the present study, rats were exposed to 1.2 LD50 GD or saline, treated with atropine sulfate (2mg/kg, im) and HI-6 (93.6mg/kg, im) 1min after GD exposure, and monitored for seizure activity. Rats were treated with diazepam (10mg/kg, sc) and caramiphen (0, 20 or 100mg/kg, im) 30min after seizure onset. Following GD exposure, performance was evaluated using a battery of behavioral tests to assess motor coordination and function, sensorimotor gating, and cognitive function. Caramiphen as adjunct to diazepam treatment attenuated GD-induced seizure activity, neuropathological damage, and cognitive deficits compared to diazepam alone, but did not attenuate the GD-induced sensorimotor gating impairment. These findings show that physiological, behavioral, and neuropathological effects of GD exposure can be attenuated by treatment with caramiphen as an adjunct to therapy, even if administration is delayed to 30min after seizure onset.
AuthorsM K Schultz, L K M Wright, M de Araujo Furtado, M F Stone, M C Moffett, N R Kelley, A R Bourne, W Z Lumeh, C R Schultz, J E Schwartz, L A Lumley
JournalNeurotoxicology and teratology (Neurotoxicol Teratol) 2014 Jul-Aug Vol. 44 Pg. 89-104 ISSN: 1872-9738 [Electronic] United States
PMID24946037 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightPublished by Elsevier Inc.
Chemical References
  • Anticonvulsants
  • Cholinesterase Inhibitors
  • Cyclopentanes
  • Oximes
  • Pyridinium Compounds
  • caramiphen edisylate
  • Atropine
  • Soman
  • asoxime chloride
  • Diazepam
Topics
  • Animals
  • Anticonvulsants (therapeutic use)
  • Atropine (therapeutic use)
  • Body Temperature (drug effects)
  • Body Weight (drug effects)
  • Brain (drug effects, pathology)
  • Cholinesterase Inhibitors (toxicity)
  • Cognition Disorders (chemically induced, drug therapy)
  • Cyclopentanes (therapeutic use)
  • Diazepam (therapeutic use)
  • Drug Therapy, Combination
  • Locomotion (drug effects)
  • Male
  • Maze Learning (drug effects)
  • Oximes (therapeutic use)
  • Pyridinium Compounds (therapeutic use)
  • Rats
  • Rats, Sprague-Dawley
  • Seizures (chemically induced, drug therapy)
  • Soman (toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: